The question „how long do you have to wait for it to start working?” actually covers three distinct issues. The first concerns how quickly any measurable changes appear after starting the use of an NAD+ precursor, i.e. the onset of action. The second concerns how long the effects of a single dose or a period of use can last after taking the product or stopping it, i.e. the duration. The third concerns how long the product remains stable or usable after reconstitution before degradation, i.e. the shelf life. In everyday discussions, these questions are often lumped together, even though the evidence behind each of them is different. In this guide, we discuss them separately.
Onset of action: how long do you have to wait for any effect?
It is important to distinguish between two different concepts: how quickly metabolites related to NAD+ change in the blood after taking a dose, and how quickly an individual may notice a subjective effect, such as a change in energy levels, mood, or another perceived parameter.
Changes in biomarkers can appear relatively quickly, although they represent only part of the overall picture. Pharmacokinetic studies show that even a single oral dose of an NAD+ precursor can cause measurable changes in NAD+-related metabolites in the blood within a few hours. In one study, single doses of 100 mg, 300 mg and 1000 mg of nicotinamide riboside were evaluated and a dose-dependent increase in the corresponding metabolites was found after just a single administration [1]. In this narrow biochemical sense, the onset of action occurs within hours, as the compound is absorbed and enters the pathways associated with NAD+ metabolism.
Sustained increases require significantly more time. The effect of a single dose on circulating metabolites is transient and does not represent a permanent shift in baseline NAD+ levels. In a Phase I pharmacokinetic study involving multiple daily administrations, blood NAD+ levels increased gradually and reached a plateau after approximately two weeks of regular daily use. Measurements of NAD+ in brain tissue changed more slowly, with measurable increases recorded after approximately four weeks of daily use [2]. This distinction is important because a single dose may alter blood biochemical parameters within hours, whereas the sustained elevation observed in longer clinical trials developed over about two weeks in the blood and about four weeks in brain tissue.
The subjective onset of action is much less clearly defined. Published clinical trials generally were not designed to determine the exact moment when someone first notices changes such as greater energy, improved sleep, better concentration or a change in mood. Most studies on NAD+ precursors evaluated functional outcomes at predetermined time points, such as 6, 8, 12 or 60 days, rather than recording precisely when the effect was first noticed. As a result, claims that people typically „feel a difference after a few days” cannot currently be precisely confirmed or ruled out based on published clinical trial data. This remains a gap in the evidence.
Duration: how long do the effects of a single dose last?
The pharmacokinetic results described above show that a single dose of the NAD+ precursor causes a transient increase in circulating metabolites, followed by a gradual decrease over the subsequent hours [1]. A single administration does not result in a sustained change in NAD+ levels. This helps to explain why major clinical trials involving nicotinamide riboside or NMN, which analyse sustained changes in NAD+-related biomarkers, have typically used multiple daily administrations rather than a single dose.
In the case of the increase achieved through regular daily use, the same pharmacokinetic study showed that after supplementation stopped, blood NAD+ levels decreased at a similarly gradual rate [2]. In other words, the elevated levels did not return to baseline immediately. They gradually approached it over a period roughly comparable to the time required for the initial increase, which was about two weeks.
The rate of increase may also vary slightly over time, even with continued daily use. In one 8-week study, the increase in whole-blood NAD+ levels was slightly lower in week 8 than in week 2 within the same dosage groups. For example, in one group an increase of 51% was recorded after two weeks compared with 48% after eight weeks, whilst in another, the increase was 142% after two weeks and 139% after eight weeks [3]. These differences were relatively small, but they demonstrate that the relationship between duration of treatment and NAD+ concentration does not necessarily follow a steadily rising linear trend.
How do the onset of action and duration differ depending on the form (oral, injection and intravenous)?
The information described above regarding the onset of action and duration of effect is derived mainly from studies on oral NR and NMN. These forms have been studied much more thoroughly in this respect than other routes of administration. The evidence regarding other delivery methods is more limited.
Intravenous NAD+ introduces the compound directly into the bloodstream, bypassing gastrointestinal absorption. One can therefore expect faster systemic exposure than following oral administration. However, no direct head-to-head studies have been established comparing the onset of action of intravenous NAD+ with oral NAD precursors. Published studies regarding intravenous NAD+ have generally used short, defined cycles rather than single isolated doses. Examples include seven consecutive daily doses in one heart failure study and four consecutive days of administration in a retrospective review of commercial intravenous therapies [4,5]. Such study designs are consistent with the broader observation that repeated exposure has most commonly been utilised when analysing sustained biological changes.
Subcutaneous or intramuscular injections have not been evaluated in controlled clinical trials with the same level of detail regarding onset of action and duration as oral or intravenous formulations. Evidence regarding these routes is therefore insufficient to determine a reliable pattern of onset or duration of action.
Sublingual and liposomal forms also lack dedicated studies in humans directly comparing their onset of action and duration with standard oral capsules. It cannot therefore be reliably stated that they work faster, slower or for a different period than standard oral forms.
Because the amount of evidence varies depending on the route of administration, approximately two weeks to achieve a sustained increase in the blood and approximately four weeks in brain tissue is the best described time frame in the literature under discussion. However, it should be emphasised that these values come specifically from studies of oral precursors [2] and should not be automatically extrapolated to other routes of administration.
How long does NAD+ remain measurable in the body?
This question partly overlaps with the issue of duration, but it is worth discussing separately. Following the cessation of regular NAD+ precursor supplementation, the elevated NAD+ levels in the blood do not appear to disappear immediately.
The pharmacokinetic studies discussed above suggest that the return towards baseline values occurs gradually, over a period roughly comparable to the time of initial increase, i.e. about two weeks [2]. This means that changes in measurable NAD+ levels may persist for some time after the end of administration rather than disappearing within a few hours.
The timing of laboratory tests can therefore influence the interpretation of results. Measuring NAD+ too early after starting supplementation, before the approximately two-week plateau described in the study, may not reflect the sustained levels observed later. Similarly, a measurement taken shortly after discontinuation may still show a residual increase before levels gradually return towards baseline values.
These observations relate to biomarker measurements and should not be interpreted as proof that subjective or clinical effects persist for the same length of time.
Storage and shelf life after reconstitution — separate from the question „how long does it work?”
Shelf life is a different issue from the biological onset of action or its duration. The question „how long can NAD+ be stored in the fridge?” concerns the physical and chemical stability of the prepared product, not how long its biological effects last after administration.
In the case of injectable NAD+ reconstituted from lyophilised, i.e. freeze-dried, powder, general pharmaceutical compounding principles are sometimes used to estimate post-preparation storage time. Depending on the compound, formulation, container, sterility conditions and available stability data, refrigerated reconstituted preparations may sometimes have a shelf-life counted in days or weeks [6].
Based on the evidence discussed, however, it is not possible to establish a single validated, universal post-reconstitution shelf-life specific to injectable NAD+. General ranges applied to other compounded or reconstituted preparations should therefore not be presented as specifically confirmed for NAD+. Priority should be given to the information on the specific product label, validated stability studies, or recommendations from a suitably qualified pharmacy or manufacturer.
Visible cloudiness, discolouration or the presence of particles may indicate that the solution should not be used, but the absence of visible changes does not confirm that the product remains chemically stable, sterile or suitable for administration. Some degradation products or microbiological contaminants may be invisible.
Oral capsules and tablets are subject to a different storage schedule, as they do not require reconstitution. Their shelf-life is usually determined by the product's expiry date and storage conditions, rather than by post-reconstitution stability.
Limitations of current evidence
- The subjective onset of action, which is the moment a person first notices a perceptible effect rather than a change in a laboratory biomarker, has not been systematically monitored in published clinical trials. This remains an evidence gap rather than a clearly established timeframe.
- The estimated half-life of approximately two weeks in the blood and four weeks in brain tissue is derived from a single Phase I pharmacokinetic study involving a relatively small number of participants [2]. Further independent studies would provide greater certainty regarding these specific estimates.
- Evidence describing the onset of action and duration of effect for injection, intravenous, sublingual and liposomal forms is considerably less developed than the evidence regarding standard oral NR and NMN preparations, which makes direct comparisons between routes of administration difficult.
- Estimates of the shelf life of reconstituted NAD+ based on general pharmaceutical compounding principles should not be interpreted as validated stability data specific to NAD+ [6].
- Changes in biomarkers do not necessarily correspond directly to subjective effects or clinically significant outcomes, and the duration of elevated NAD+ levels should not automatically be taken as an indication of the duration of health benefits.
Disclaimer
This article is intended solely for educational and scientific purposes. It does not constitute medical advice, a diagnosis, treatment recommendations, dosage information or advice on the use of NAD+, NAD+ precursors or injectable products.
NAD+ and its precursors should not be presented as FDA- or EMA-approved methods for the prevention, treatment, or cure of diseases, unless referring to a specific approved medicinal product and indication. Changes in NAD+-related biomarkers do not in themselves constitute proof of clinical benefit.
Before starting to use a new supplement or injectable product, you should consult a qualified healthcare professional or pharmacist. Decisions regarding storage, handling and shelf life should be based on validated information specific to the product or appropriate pharmaceutical recommendations, rather than generalised post-reconstitution timeframes.
References
[1] Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
[2] Berven, H., Svensen, M., Eikeland, H., Tvedten, N., Sheard, E. V., Amdahl Af Geijerstam, S., Søgnen, M., McCann, A., Arnsten, L., Årseth, O., Skjeie, V., Hjellbrekke, A., Skeie, G.-O., Torres Cleuren, Y. N., Nido, G. S., Haugarvoll, K., Riemer, F., Tzoulis, C., & Dölle, C. (2026). The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience, 29(3), 114764. https://doi.org/10.1016/j.isci.2026.114764
[3] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomised, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[4] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischaemic cardiomyopathy: A randomised, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[5] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582
[6] Empower Pharmacy. (2025). How to prepare a lyophilised powder for injection. Empower Pharmacy Patient Resources. https://www.empowerpharmacy.com/compound-medication/medication-instructions/how-to-prepare-lyophilized-powder-for-injection/